Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Trial details
- Registry ID
- NCT06767514
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1NCT06767514 | Summit Therapeutics | Phase 3 | Recruiting | 2028-04Estimated |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsNCT05899608 | Summit Therapeutics | Phase 3 | Active not recruiting | 2028-12-31Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |